Rekombinanter TNFRSF4 (Telazorlimab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter TNFRSF4 (Telazorlimab Biosimilar) Antikörper (ABIN7676097)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (telazorlimab)
-
Sequenz
- QVTLKESGPA LVKPTQTLTL TCSFSGFSLS TSGMGVGWIR QPPGKALEWI AHIWWDDDKY YNTALKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI DWDGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK,EIVLTQSPAT LSLSPGERAT LSCRASSSVS YMHWYQQKPG QAPRPWIYAT SNRATGIPAR FSGSGSGTDY TLTISSLEPE DFAVYYCQQW SSNPWTFGQG TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
-
Produktmerkmale
- Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (telazorlimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: OX40 inhibitors
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- TNFRSF4 (Telazorlimab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- P43489
Target
-